The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC Sept 2021 | The importance of METex14 testing in NSCLC
Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, Fairfax, VA, emphasizes the importance of MET Exon 14 (METex14) mutation testing in patients with non-small cell lung cancer (NSCLC), as well as biomarker testing in general to allow patients to be offered targeted therapies. He highlights that patients with NSCLC that test positive for METex14 skipping mutations should be offered capmatinib and tepotinib in all lines of therapy. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.
